Trials / Completed
CompletedNCT02673476
A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Alios Biopharma Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is being to see how effective and safe ALS-008176 is in treating adults in the hospital with a Respiratory Syncytial Virus-Related Illness.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALS-008176 | ALS-008176 tablets |
| DRUG | Placebo | Identical placebo tablets |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2016-10-31
- Completion
- 2016-10-31
- First posted
- 2016-02-04
- Last updated
- 2025-02-04
Locations
21 sites across 5 countries: United States, Australia, New Zealand, Singapore, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02673476. Inclusion in this directory is not an endorsement.